ImVisioN Therapeutics
Hanover
About ImVisioN Therapeutics
ImVisioN Therapeutics is pioneering ILIT, a proprietary technology for the delivery of immunotherapy in the treatment of allergies. ILIT is clinically proven and has been shown to be a safer, more effective means of delivering allergy therapeutics. By applying another technology called modular antigen transporter (MAT), ImVisioN leverages the potential of ILIT to develop drugs that use allergens safely for specific and highly effective antigen presentation. In addition to the company’s lead product for the treatment of cat dander allergy, it also has programs addressing birch pollen and house dust mite allergies.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Total funding: $4.1M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2008)
Industries & Categories
Biotechnology, Life Science, Therapeutics
Canonical: https://fsome.com/organization/imvision-therapeutics-2055520 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.